News

Medtronic starts U.S. trials of pain relief neurostimulator

Medtronic Inc. (NYSE: MDT) has begun clinical trials of a neurostimulator designed for patients suffering from chronic pain. The RestoreSensor neurostimulator is unique because it uses a proprietary sensor that enables it to adjust the amount of electricity  being delivered to a patient based on the patient’s body position, according to a statement from Medtronic. […]

Medtronic Inc. (NYSE: MDT) has begun clinical trials of a neurostimulator designed for patients suffering from chronic pain.

The RestoreSensor neurostimulator is unique because it uses a proprietary sensor that enables it to adjust the amount of electricity  being delivered to a patient based on the patient’s body position, according to a statement from Medtronic.

The amount of electricity required for a neurostimulator to block pain signals from reaching a patient’s brain differs based on body position. That’s because adjustments to body position change the distance between the spinal cord and the neurostimulator’s implanted electrodes.

Sponsored Post

Physician Targeting Using Real-time Data: How PurpleLab’s Alerts Can Help

By leveraging real-time data that offers unprecedented insights into physician behavior and patient outcomes, companies can gain a competitive advantage with prescribers. PurpleLab®, a healthcare analytics platform with one of the largest medical and pharmaceutical claims databases in the United States, recently announced the launch of Alerts which translates complex information into actionable insights, empowering companies to identify the right physicians to target, determine the most effective marketing strategies and ultimately improve patient care.

Typically patients use a remote-control device to adjust their neurostimulator when they change positions. However, the RestoreSensor removes the need for patients to make adjustments because its sensor allows the device to make the adjustments itself, using Medtronic’s AdaptiveStim technology, according to the company.

The device has already received European regulatory approval. The U.S. trials will be conducted at 10 locations, with the first implant already performed at Minneapolis’ MAPS Pain Clinic.

Medtronic hopes to launch the RestoreSensor in the U.S. in the first quarter of its fiscal 2012 and estimates its market size at $1 billion.

Last quarter, revenue in Medtronic’s neuromodulation business grew 11 percent to $394 million.